SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib

ConclusionsOur findings suggest that IM secondary resistance is associated with the elevation of S1P, and blockage the signaling pathway of SPK1/S1P warrants evaluation as a potential therapeutic strategy in IM-resistant GISTs.Graphical abstractThe design of this study from blood management, group information collection, IM plasma concentration with different elements, identification of sphingolipid metabolism and lastly verification the function of SPK1/S1P in the IM-resistance GISTs cells.

http://rd.springer.com/10.1007/s10120-022-01332-7

Source: Gastric Cancer - August 24, 2022 Category: Gastroenterology Source Type: research